Evidence map›Paper›PMID 36349616›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2022

Size optimization of carfilzomib nanocrystals for systemic delivery to solid tumors.

Hytham H Gadalla, Seongsoo Lee, Hyungjun Kim, Abigail T Armstrong, Dina Fathalla, Fawzia Habib, Hyunyoung Jeong, Wooin Lee, Yoon Yeo

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Hytham H GadallaDepartment of Industrial and Physical Pharmacy, Purdue University, 575 West Stadium Avenue, West Lafayette, IN 47907, USA; Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
Seongsoo LeeCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
Hyungjun KimDepartment of Industrial and Physical Pharmacy, Purdue University, 575 West Stadium Avenue, West Lafayette, IN 47907, USA; Department of Chemistry and Bioscience, Kumoh National Institute of Technology, 61 Daehak-ro, Gumi, Gyeongbuk 39177, Republic of Korea.
Abigail T ArmstrongDepartment of Industrial and Physical Pharmacy, Purdue University, 575 West Stadium Avenue, West Lafayette, IN 47907, USA.
Dina FathallaDepartment of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
Fawzia HabibDepartment of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
Hyunyoung JeongDepartment of Industrial and Physical Pharmacy, Purdue University, 575 West Stadium Avenue, West Lafayette, IN 47907, USA; Department of Pharmacy Practice, Purdue University, West Lafayette, IN 47907, USA.
Wooin LeeCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea. Electronic address: wooin.lee@snu.ac.kr.
Yoon YeoDepartment of Industrial and Physical Pharmacy, Purdue University, 575 West Stadium Avenue, West Lafayette, IN 47907, USA; Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN 47907, USA. Electronic address: yyeo@purdue.edu.
Purdue University West Lafayette · USAssiut University · EGSeoul National University · KRKumoh National Institute of Technology · KR

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI ANDREW D MESECAR · 1985 to 2026
$43.4M
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancerR01CA258737 · NCI · PURDUE UNIVERSITY · PI KRON, STEPHEN J., YEO, YOON · 2021 to 2024
$2.3M
Chemotherapy delivery with nanoparticles for targeted induction of immunogenic cell deathR01CA232419 · NCI · PURDUE UNIVERSITY · PI YEO, YOON · 2018 to 2022
$2.0M
NCI NIH HHS P30 CA023168NCI NIH HHS R01 CA232419NCI NIH HHS R01 CA258737
6 · The paper itself

Abstract

Carfilzomib (CFZ) is a second-generation proteasome inhibitor effective in blood cancer therapy. However, CFZ has shown limited efficacy in solid tumor therapy due to the short half-life and poor tumor distribution. Albumin-coated nanocrystal (NC) formulation was shown to improve the circulation stability of CFZ, but its antitumor efficacy remained suboptimal. We hypothesize that NC size reduction is critical to the formulation safety and efficacy as the small size would decrease the distribution in the reticuloendothelial system (RES) and selectively increase the uptake by tumor cells. We controlled the size of CFZ-NCs by varying the production parameters in the crystallization-in-medium method and compared the size-reduced CFZ-NCs (z-average of 168 nm, NC

Indexed as

Antineoplastic AgentsNanoparticlesAnimalsCell Line, TumorMiceOligopeptidesProteasome InhibitorsTissue DistributionAntineoplastic AgentscarfilzomibOligopeptidesProteasome InhibitorsBiodistributionCancer chemotherapyNanocrystalsProteasome inhibitorReticuloendothelial uptakeSize optimization

Identifiers

PMID36349616
PMCPMC9737058
OpenAlexW4308266190

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.